Advertisement
ELV vs HUM
Which Stock Would AI Choose? Elevance Health (ELV) vs. Humana (HUM) Stock Comparison
Key Takeaways
- Elevance Health (ELV) and Humana (HUM) are both major managed care organizations in the U.S. health insurance sector, with comparable exposure to Medicare Advantage and commercial lines.
- In recent weeks, ELV reported Q2 2026 results that beat estimates and prompted a modest upward revision to full-year adjusted earnings per share (EPS) guidance.
- HUM has delivered stronger year-to-date price appreciation than ELV through late July 2026, supported by analyst upgrades and reaffirmed full-year outlook ahead of its Q2 earnings release.
- Both companies maintain solid balance sheets and return capital to shareholders via dividends and buybacks, though HUM’s higher valuation multiples reflect its recent momentum.
- Sector-wide factors such as medical cost trends and Medicare reimbursement dynamics continue to influence sentiment for both stocks in the current market environment.
- Relative performance has favored HUM on a year-to-date basis, while ELV’s post-earnings stability offers a contrast in risk profile.
Introduction
This comparison examines Elevance Health (ELV) and Humana (HUM), two leading managed care organizations that provide health insurance and related services to millions of members. Both stocks operate within the same regulatory and reimbursement environment, making them relevant for investors seeking exposure to the U.S. healthcare sector. Traders and portfolio managers evaluating relative value, momentum, and sector positioning in managed care may find this analysis useful for understanding how the companies’ recent financial results and market activity differ.
Elevance Health (ELV) Overview and Recent Performance
Elevance Health (ELV) operates as a diversified managed care company offering commercial, Medicare, and Medicaid health plans, along with pharmacy benefit management and healthcare services through its Carelon segment. In recent market activity, the stock traded near $378 following its July 15, 2026 earnings release. The company reported second-quarter operating revenue of $49.8 billion and adjusted diluted EPS of $7.45, both above consensus estimates, leading to a raised full-year 2026 guidance. Share repurchases and a consistent quarterly dividend of $1.72 have supported shareholder returns. Sentiment has remained steady amid broader sector volatility, with the stock showing resilience after earlier 2026 gains.
Humana (HUM) Overview and Recent Performance
Humana (HUM) focuses primarily on Medicare Advantage and commercial health insurance, supplemented by pharmacy solutions and clinical programs. As of late July 2026, the stock traded near $389 ahead of its scheduled July 29 earnings release. Year-to-date price performance has been robust, supported by reaffirmed 2026 EPS guidance and recent analyst upgrades citing favorable medical cost trends. The company’s emphasis on government programs has contributed to revenue growth, while capital returns through dividends and buybacks remain active. Recent market activity reflects cautious optimism as investors await detailed quarterly results.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a pool of hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters. Only those demonstrating the strongest alignment with prevailing market conditions—measured by backtested performance metrics, consistency, and adaptability—earn placement in the trending section. Available bots exhibit a wide range of historical win rates, profit factors, and drawdown profiles, allowing users to review detailed statistics before deployment. The section provides an informational resource for traders exploring automated strategies across equities. Review the Trending AI Robots page to examine current selections and associated performance data.
Head-to-Head Comparison
Elevance Health (ELV) and Humana (HUM) share similar business models centered on health plan administration but differ in scale and emphasis. ELV maintains a broader commercial and Medicaid footprint alongside Medicare, while HUM derives a larger proportion of revenue from Medicare Advantage. Recent momentum has favored HUM on a year-to-date basis, with stronger price appreciation reflecting analyst sentiment around earnings visibility. ELV’s post-earnings guidance raise provided near-term support, yet its valuation multiples remain more moderate compared with HUM. Risk factors for both include medical loss ratio pressures and regulatory changes affecting reimbursement. Sector exposure is nearly identical, though HUM’s pending earnings introduce short-term event risk not present for ELV following its recent report. Market sentiment currently tilts toward HUM’s growth narrative, while ELV offers a profile of measured stability.
Tickeron AI Verdict
Based on observable factors such as recent earnings delivery, guidance revisions, and relative price momentum through late July 2026, Tickeron’s AI models currently assign a probabilistic edge to Humana (HUM). Stronger year-to-date performance and constructive analyst revisions provide measurable tailwinds, though the upcoming earnings release introduces uncertainty. Elevance Health (ELV) demonstrates consistent execution and post-report stability that could narrow the gap if broader sector conditions remain favorable. The assessment reflects pattern recognition across trend consistency and catalyst timing rather than a definitive ranking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELV is a Buy and HUM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELV’s FA Score shows that 2 FA rating(s) are green whileHUM’s FA Score has 2 green FA rating(s).
- ELV’s FA Score: 2 green, 3 red.
- HUM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELV’s TA Score shows that 4 TA indicator(s) are bullish while HUM’s TA Score has 4 bullish TA indicator(s).
- ELV’s TA Score: 4 bullish, 4 bearish.
- HUM’s TA Score: 4 bullish, 5 bearish.
Price Growth
ELV (@Managed Health Care) experienced а -0.49% price change this week, while HUM (@Managed Health Care) price change was -6.54% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was -2.68%. For the same industry, the average monthly price growth was -9.13%, and the average quarterly price growth was +40.99%.
Reported Earning Dates
ELV is expected to report earnings on Oct 21, 2026.
HUM is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Managed Health Care (-2.68% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| ELV | HUM | ELV / HUM | |
| Capitalization | 81.5B | 43.7B | 186% |
| EBITDA | N/A | N/A | - |
| Gain YTD | 8.314 | 43.119 | 19% |
| P/E Ratio | 16.62 | 34.39 | 48% |
| Revenue | 201B | 146B | 138% |
| Total Cash | 36B | 23.9B | 151% |
| Total Debt | 31B | 14.2B | 218% |
ELV | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 94 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 50 | 37 | |
P/E GROWTH RATING 1..100 | 22 | 11 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ELV's Valuation (6) in the Managed Health Care industry is in the same range as HUM (10). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
ELV's Profit vs Risk Rating (94) in the Managed Health Care industry is in the same range as HUM (100). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
HUM's SMR Rating (95) in the Managed Health Care industry is in the same range as ELV (98). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
HUM's Price Growth Rating (37) in the Managed Health Care industry is in the same range as ELV (50). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
HUM's P/E Growth Rating (11) in the Managed Health Care industry is in the same range as ELV (22). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
| ELV | HUM | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 69% |
| Stochastic ODDS (%) | 4 days ago 62% | 4 days ago 67% |
| Momentum ODDS (%) | 4 days ago 62% | 4 days ago 65% |
| MACD ODDS (%) | 4 days ago 65% | 4 days ago 55% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 65% |
| TrendMonth ODDS (%) | 4 days ago 56% | 4 days ago 67% |
| Advances ODDS (%) | 7 days ago 56% | 20 days ago 61% |
| Declines ODDS (%) | 11 days ago 57% | 8 days ago 66% |
| BollingerBands ODDS (%) | 4 days ago 70% | 4 days ago 67% |
| Aroon ODDS (%) | N/A | 4 days ago 67% |
Advertisement
ELV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELV has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ELV jumps, then UNH could also see price increases.
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been loosely correlated with UNH. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if HUM jumps, then UNH could also see price increases.